CHEBI:170007 - nirmatrelvir

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name nirmatrelvir
ChEBI ID CHEBI:170007
Definition An azabicyclohexane that is (1R,5S)-3-azabicyclo[3.1.0]hexane substituted by {(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}aminoacyl, 3-methyl-N-(trifluoroacetyl)-L-valinamide, methyl and methyl groups at positions 2S, 3, 6 and 6, respectively. It is the first orally administered inhibitor of SARS-CoV-2 main protease developed by Pfizer and used in combination with ritonavir for the treatment of COVID-19.
Stars This entity has been manually annotated by the ChEBI Team.
Secondary ChEBI IDs CHEBI:192699
Supplier Information
Download Molfile XML SDF
more structures >>
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C23H32F3N5O4
Net Charge 0
Average Mass 499.535
Monoisotopic Mass 499.24064
InChI InChI=1S/C23H32F3N5O4/c1-21(2,3)16(30-20(35)23(24,25)26)19(34)31-10-13-14(22(13,4)5)15(31)18(33)29-12(9-27)8-11-6-7-28-17(11)32/h11-16H,6-8,10H2,1-5H3,(H,28,32)(H,29,33)(H,30,35)/t11-,12-,13-,14-,15-,16+/m0/s1
InChIKey LIENCHBZNNMNKG-OJFNHCPVSA-N
SMILES [H][C@]12CN([C@H](C(=O)N[C@@H](C[C@]3([H])CCNC3=O)C#N)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)C(F)(F)F)C(C)(C)C
Roles Classification
Biological Role(s): EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
An EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69).
anticoronaviral agent
Any antiviral agent which inhibits the activity of coronaviruses.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing nirmatrelvir (CHEBI:170007) has role anticoronaviral agent (CHEBI:149553)
nirmatrelvir (CHEBI:170007) has role EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor (CHEBI:147285)
nirmatrelvir (CHEBI:170007) is a azabicyclohexane (CHEBI:170008)
nirmatrelvir (CHEBI:170007) is a nitrile (CHEBI:18379)
nirmatrelvir (CHEBI:170007) is a organofluorine compound (CHEBI:37143)
nirmatrelvir (CHEBI:170007) is a pyrrolidin-2-ones (CHEBI:74223)
nirmatrelvir (CHEBI:170007) is a pyrrolidinecarboxamide (CHEBI:46770)
nirmatrelvir (CHEBI:170007) is a secondary carboxamide (CHEBI:140325)
nirmatrelvir (CHEBI:170007) is a tertiary carboxamide (CHEBI:140326)
Incoming Paxlovid (CHEBI:192712) has part nirmatrelvir (CHEBI:170007)
IUPAC Name
(1R,2S,5S)-N-{(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide
INNs Sources
nirmatrelvir WHO MedNet
nirmatrelvir WHO MedNet
nirmatrelvir WHO MedNet
nirmatrelvirum WHO MedNet
Synonyms Sources
PF 07321332 ChEBI
PF-07321332 ChemIDplus
PF07321332 ChEBI
Manual Xrefs Databases
D12244 KEGG DRUG
DB16691 DrugBank
Nirmatrelvir Wikipedia
View more database links
Registry Number Type Source
2628280-40-8 CAS Registry Number ChemIDplus
Citations Waiting for Citations Types Sources
34687004 PubMed citation Europe PMC
35073029 PubMed citation Europe PMC
35153195 PubMed citation Europe PMC
35182772 PubMed citation Europe PMC
35183067 PubMed citation Europe PMC
35203821 PubMed citation Europe PMC
35305258 PubMed citation Europe PMC
35335157 PubMed citation Europe PMC
35389231 PubMed citation Europe PMC
35425393 PubMed citation Europe PMC
35461811 PubMed citation Europe PMC
35477935 PubMed citation Europe PMC
35505633 PubMed citation Europe PMC
35640480 PubMed citation Europe PMC
35678736 PubMed citation Europe PMC
35702394 PubMed citation Europe PMC
35845944 PubMed citation Europe PMC
36276807 PubMed citation Europe PMC
36574296 PubMed citation Europe PMC
36965419 PubMed citation Europe PMC
37074087 PubMed citation Europe PMC
37402789 PubMed citation Europe PMC
37510996 PubMed citation Europe PMC
37947496 PubMed citation Europe PMC
38257765 PubMed citation Europe PMC
38399271 PubMed citation Europe PMC
38432955 PubMed citation Europe PMC
38553607 PubMed citation Europe PMC
PMC9232762 PubMed Central citation Europe PMC
PMC9264725 PubMed Central citation Europe PMC
Last Modified
16 April 2024
General Comment
2021-04-26 Further info: https://cen.acs.org/acs-news/acs-meeting-news/Pfizer-unveils-oral-SARS-CoV/99/i13